Skip to main content
. 2015 Sep 15;4:25. doi: 10.1186/s40164-015-0020-3

Fig. 1.

Fig. 1

Idarucizumab binds and inactivates dabigatran. Idarucizumab is the first-in-class dabigatran-specific antidote. It is a humanized monoclonal antibody fragment [Fab] that binds specifically to and inactivates dabigatran